Dr. Noah Berkowitz is Chief Medical Officer at Arvinas and responsible for clinical development of the company’s PROTAC protein degrader programs in oncology and neuroscience. Dr. Berkowitz has more than 20 years of experience in advancing programs through early and late stages of development, with proven ability in leading clinical development, regulatory, and medical affairs. He has led multidisciplinary teams and has extensive knowledge of clinical trial design and execution.
Prior to joining Arvinas, Dr. Berkowitz was Senior Vice President and Development Unit Head of Hematology at Bristol Myers Squibb (BMS). While at BMS, Dr. Berkowitz’s teams achieved initial or subsequent global indications for Abecma®, Breyanzi®, Reblozyl®, Onureg®, and Inrebic®, managed development life cycles for Revlimid®, Pomalyst®, and Sprycel®, and initiated and/or designed registration trials for iberdomide, mezigdomide, and alnuctamab. Before BMS, Dr. Berkowitz held roles of increasing responsibility in the areas of oncology, rare diseases, and hematology at Novartis, most recently as Vice President and Clinical Development Head for Hematology. Earlier in his career, Dr. Berkowitz was an executive at Impath (acquired by Genzyme) and founder and Chief Executive Officer of Synvista.
Dr. Berkowitz trained in Medical Oncology at the National Cancer Institute and received his M.D., Ph.D., from Columbia University.
What is Noah Berkowitz's net worth?
The estimated net worth of Noah Berkowitz is at least $2.20 million as of March 18th, 2026. Dr. Berkowitz owns 202,503 shares of Arvinas stock worth more than $2,197,158 as of April 5th. This net worth estimate does not reflect any other investments that Dr. Berkowitz may own. Learn More about Noah Berkowitz's net worth.
How do I contact Noah Berkowitz?
Has Noah Berkowitz been buying or selling shares of Arvinas?
Noah Berkowitz has not been actively trading shares of Arvinas during the last ninety days. Most recently, Noah Berkowitz sold 6,435 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $11.10, for a transaction totalling $71,428.50. Following the completion of the sale, the insider now directly owns 202,503 shares of the company's stock, valued at $2,247,783.30. Learn More on Noah Berkowitz's trading history.
Who are Arvinas' active insiders?
Arvinas' insider roster includes Noah Berkowitz (Chief Medical Officer), Sean Cassidy (CFO), John Houston (CEO), David Loomis (CAO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Andrew Saik (Chief Financial Officer and Treasurer), Timothy Shannon (Director), Ian Taylor (Insider), and Randy Teel (CEO). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?
In the last year, Arvinas insiders bought shares 2 times. They purchased a total of 50,000 shares worth more than $495,100.00. In the last year, insiders at the sold shares 10 times. They sold a total of 69,794 shares worth more than $848,094.43. The most recent insider tranaction occured on March, 18th when insider Noah Berkowitz sold 6,435 shares worth more than $71,428.50. Insiders at Arvinas own 4.7% of the company.
Learn More about insider trades at Arvinas. Information on this page was last updated on 3/18/2026.
